Belogent ointment 15g
Dosage:
0.05% x 15g
0.05% x 30g
0.05% x 40g
0.05% + 0.1% x 15g
0.05% + 0.1% x 30g
0.05% + 0.1% x 40g
Release form:
Cream
Ointment
Category
Psoriasis
Scope of the drug
Leather
Release form
Ointment
Manufacturer country
Croatia
Package quantity, pcs
one
Release form
Ointment for external use
Packaging
Tube 15 g.
pharmachologic effect
Anti-inflammatory, anti-allergic, antibacterial, antipruritic.
Belogent has anti-inflammatory, anti-allergic, anti-proliferative and antipruritic effects.
When Belogent is applied to the surface of the skin, it has a quick and strong effect in the inflammation focus, reducing the severity of objective symptoms (erythema, edema, lichenification) and subjective sensations (itching, irritation, pain).
Indications
Dermatoses, allergic and inflammatory skin diseases that respond to topical corticosteroid therapy, the course of which is complicated by a bacterial infection or there is a danger of its addition in children from 1 year of age and in adults:
eczema, diffuse neurodermatitis
dermatitis - atopic, contact (including professional), allergic, seborrheic
Infected dermatitis resulting from insect bites
impetigo
psoriasis
lichen planus
phleboderma
anogenital itching.
Contraindications
hypersensitivity to betamethasone, gentamicin and other components of Belogent
viral skin infections, skin post-vaccination reactions
open wounds, trophic ulcers
acne vulgaris, rosacea
chickenpox
cutaneous manifestations of syphilis
lupus.
Application during pregnancy and lactation
Perhaps if the expected effect of therapy outweighs the potential risk to the fetus.
During pregnancy, the use of Belogent should not be prolonged and, if possible, be limited to small areas of the skin.
During breastfeeding - only for strict indications, but you cannot apply Belogent to the mammary gland before feeding.
special instructions
Belogent is intended for external use only.
Long-term use of the drug on the skin of the face is not recommended.
development of rosacea, perioral dermatitis and acne is possible.
Belogent should not be used in the eye area, due to the likelihood of getting the drug on the mucous membrane, which can contribute to the development of cataracts, glaucoma, fungal eye infections and exacerbation of herpes infection.
Structure
1 g contains 0.64 mg betamethasone dipropionate (corresponding to 0.5 mg betamethasone), gentamicin sulfate (calculated as base) 1 mg
Method of administration and dosage
Belogen is applied to the affected area of ��the skin with a thin layer, rubbing slightly, 2 times a day.
Side effects
They are mild.
Rarely (as with the use of other GCS), hypersensitivity reactions (burning, itching, redness), acne-like changes, hypopigmentation, striae, skin atrophy, hypertrichosis, telangiectasia may develop.
If hypersensitivity reactions occur, therapy should be discontinued and a doctor should be consulted.
Storage conditions
In a dry, dark place at a temperature not exceeding 25 В° C.
Shelf life
4 years.
Active substance
Betamethasone, Gentamicin
Possible product names
BELOGENT 15.0 OINTMENT BELOGENT 15G.
OINTMENT Belogent ointment, 15 g BELOGENT OINTMENT 15g Belogent ointment for external approx.
15g Tube
Name ENG
BELOGENT
Clinical and pharmacological group
Drug with antibacterial and anti-inflammatory action for external use
ATX code
Betamethasone in combination with antibiotics
Dosage
0.05% + 0.1% x 15g
Structure
1 g of ointment contains betamethasone dipropionate 0.64 mg (corresponds to 0.5 mg betamethasone), gentamicin sulfate (in terms of base) 1 mg, excipients: chlorocresol, sodium dihydrogen phosphate monohydrate, phosphoric acid, soft white paraffin, liquid paraffin, macrogol cetostearate, cetostearyl alcohol [60% cetyl alcohol, 40% stearyl alcohol], sodium hydroxide, water.
Indications
Dermatoses, allergic and inflammatory skin diseases that respond to topical corticosteroid therapy, the course of which is complicated by a bacterial infection or there is a danger of its addition in children from 1 year of age and in adults:
eczema, diffuse neurodermatitis
dermatitis atopic, contact (including professional), allergic, seborrheic
Infected dermatitis resulting from insect bites
impetigo
psoriasis
lichen planus
phleboderma
anogenital itching.
Contraindications
Hypersensitivity to betamethasone, gentamicin and other components of Belogent
viral skin infections, skin post-vaccination reactions
open wounds, trophic ulcers
acne vulgaris, rosacea
chickenpox
cutaneous manifestations of syphilis
lupus.
INN / Active ingredient
betamethasone, gentamicin (sulfate form)
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 4 years
Specifications
Category
Psoriasis
Scope of the drug
Leather
Release form
Ointment
Manufacturer country
Croatia
Package quantity, pcs
one
Minimum age from
1 year
Way of introduction
Locally
,
On the skin
,
Outwardly
Vacation conditions
Without recipe
Brand name
Belupo
The amount of the dosage form in the primary package
15 g
Primary packaging type
Tuba
Type of consumer packaging
Pack of cardboard
Anatomical and therapeutic characteristics
D07CC01 Betamethasone, in combination with antibiotics
Dosage form
Ointment for external use
Expiration date in days
1095
The target audience
Children
Package weight, g
25
Mode of application
:
Outwardly, Belogent ointment is applied to the affected area of ��the skin with a thin layer, gently rubbing, 2 times a day.
Pharmaco-therapeutic group
:
Topical glucocorticosteroid + antibiotic aminoglycoside
Dosage (volume) of the substance in the preparation
:
betamethasone dipropionate 0.64 mg (corresponds to 0.5 mg of betamethasone), gentamicin sulfate (in terms of base) 1 mg
Information on technical characteristics, delivery set, country of manufacture